Monoclonal antibodies (mAbs) are now established as targeted therapies for malignancies,
transplant rejection, autoimmune and infectious diseases, as well as a range of new …

Background Epidermal growth factor receptor inhibitors (EGFRI) produce various
dermatologic side effects in the majority of patients, and guidelines are crucial for the …

Answer questions and earn CME/CNE Advances in genomics and molecular biology have
identified aberrant proteins in cancer cells that are attractive targets for cancer therapy …

Purpose Panitumumab, a fully human monoclonal antibody targeting the epidermal growth
factor receptor (EGFR), is approved in the United States and Europe for the treatment of …

There has been a rapid emergence of numerous targeted agents in the oncology community
in the last decade. This exciting paradigm shift in drug development lends promise for the …

Highlights•This ESMO Clinical Practice Guideline provides recommendations on the
prevention/management of dermatological toxicities.•Authorship includes a multidisciplinary …

The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors
has increased considerably in recent years. Currently, they are approved in non-small cell …

Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon,
pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase …

Background Patients treated with epidermal growth factor receptor inhibitors (EGFRIs)
frequently experience dermatologic toxic effects. Whereas the impact of these effects on …

The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor
tyrosine kinases, plays an important role in the control of cell growth and differentiation …